Navigation Links
CELEXION Awarded Patent on Biosynthesis of Renewable Chemicals
Date:3/14/2012

CAMBRIDGE, Mass., March 14, 2012 /PRNewswire-iReach/ -- CELEXION LLC today announced the issuance of US Patent number 8,133,704 by the US Patent and Trademark Office entitled "Biological synthesis of difunctional alkanes from carbohydrate feedstocks."  The patent was issued on March 13, 2012 and covers biological methods of converting renewable feedstocks into a variety of high-value chemicals with a total market value of over $10B.

"At CELEXION, we leverage the power of biological systems to make new, high performance products and to make everyday products more functional, affordable, and sustainable," said Dr. Brian M. Baynes, CEO of CELEXION and co-inventor of the technology.  "The methods disclosed in this patent enable a variety of important bulk chemicals to be synthesized from renewable starting materials using biological catalysts.  The efficiency of this approach makes our products not only sustainable, but also less expensive than their petroleum-derived equivalents."

Claims of the '704 patent include key biosynthetic steps from common metabolic intermediates and their uses in manufacturing a family of chemicals including adipic acid, caprolactam, hexamethylenediamine, pimelic acid, and caprolactone.  These chemicals are key components in a wide variety of packaging, materials, polymers, and other industrial and consumer applications.

About CELEXION
CELEXION LLC is a bioengineering company that develops powerful platform technologies and products for partners in the pharmaceutical, industrial, agricultural, and consumer sectors. The company's technologies include the SECANT platform for engineering high performance protein products, a library of human antibodies for therapeutic lead generation, enzymatic pathways for synthesis of a variety of high-value chemicals and materials from wastes and other inexpensive precursors, and a novel family of enzymes for manipulation of chromosome-sized DNA.  CELEXION is headquartered in Cambridge, MA, USA.  For further information, please visit our website at www.celexionbio.com.

CELEXION and SECANT are registered trademarks of Celexion LLC.

Media Contact: Celexion Business Development, Celexion LLC, +1-617-500-3011 x1, info@celexionbio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE CELEXION LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chemring Detection Systems Awarded $9M for Biological Detection Systems
2. Leading German Researcher Awarded Elseviers 2011 Tetrahedron Prize
3. Chemring Detection Systems Awarded $500k for Strategic Research and Development
4. Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year
5. Sloan Research Fellowships Awarded to 126 Young Scholars
6. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
7. Chinese Scientists Zhen-Yi Wang and Zhu Chen Awarded 7th Annual Szent-Gyorgyi Prize for Progress in Cancer Research
8. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
9. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
10. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
11. BioPower Systems Awarded $5 Million from Victorian Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... 20, 2017 , ... G&L Scientific Inc, a leading provider ... ), has announced the opening of new offices in Cambridge, Massachusetts, strengthening and ... This is the latest step in G&L’s expansion of its global clinical consulting ...
(Date:1/21/2017)... Jan. 20, 2017 Aratana Therapeutics, Inc. (NASDAQ: ... on the licensing, development and commercialization of innovative biopharmaceutical ... Best Company in North America ... award based on the FDA approval of three ... ENTYCE ® (capromorelin oral solution) and NOCITA ® ...
(Date:1/20/2017)... -- http://www.Financialbuzz.com - According to ... of death worldwide. There were 8.2 million cancer related ... deaths increased gradually over time, the death rates have ... cancers continues to drive demand of biological therapies for ... Insights, Inc. cancer biological therapy market size was USD 61.3 ...
(Date:1/19/2017)... -- WuXi AppTec, a leading global pharmaceutical, biotechnology ... today announced that it has acquired HD Biosciences ... contract research organization (CRO). After completion of acquisition, ... WuXi, and will continue to focus on growing ... acquisition will further strengthen WuXi,s R&D capability from ...
Breaking Biology Technology:
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
(Date:1/11/2017)... 2017 Intoxalock, a leading ignition interlock provider, ... its patent-pending calibration device. With this new technology, Intoxalock ... upload data logs and process repairs at service center ... "Fighting drunk driving through the application of cutting-edge technologies ... but also for the customer who can get back ...
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CES® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
Breaking Biology News(10 mins):